Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities-a Multicenter Study

被引：0

作者：

Chang, Darryl ^{[1
,2
]}

Habib, Alma ^{[2
,3
]}

Uegel, Andrew ^{[2
,4
]}

Struble, Emily ^{[2
,4
]}

Shaikh, Hira ^{[2
,4
]}

Strouse, Christopher ^{[2
,4
]}

Green, Kimberly M. ^{[2
,5
]}

Mushtaq, Muhammad Umair ^{[2
,6
]}

Mahmoudjafari, Zahra ^{[2
,6
]}

Hashmi, Hamza ^{[2
,7
]}

Mcguirk, Joseph P. ^{[2
,8
]}

Khan, Abdullah Mohammad ^{[2
,3
]}

Abdallah, Al-Ola ^{[2
,8
]}

Ahmed, Nausheen ^{[2
,6
]}

Atrash, Shebli ^{[1
,2
]}

Bhutani, Manisha ^{[1
,2
]}

机构：

[1] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[2] US Myeloma Innovat Res Collaborat USMIRC, Kansas City, KS USA

[3] Ohio State Univ, Div Hematol, Columbus, OH USA

[4] Univ Iowa Hosp & Clin, Div Hematol Oncol & Blood & Marrow Transplantat, Iowa, LA USA

[5] Med Univ South Carolina, Div Hematol Oncol, Charleston, SC USA

[6] Univ Kansas, Div Hematol Malignancies & Cellular Therapeut, Med Ctr, Westwood, KS USA

[7] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, New York, NY USA

[8] Univ Kansas, Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Kansas City, KS USA

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-208692

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2404 / 2405

页数：2

共 50 条

[1] Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study
Merz, Maximilian
Albici, Anca-Maria
von Tresckow, Bastian
Rathje, Kristin
Fenk, Roland
Holderried, Tobias
Mueller, Fabian
Tovar, Natalia
Oliver-Caldes, Aina
Vucinic, Vladan
Kharboutli, Soraya
Baermann, Ben-Niklas
Ayuk, Francis
Platzbecker, Uwe
Stoelzel, Friedrich
Schub, Nathalie
Schmitz, Friederike
Fandrei, David
Born, Patrick
Khandanpour, Cyrus
Hanoun, Christine
Hoerster, Keven
Teichert, Marcel
Jeker, Barbara
Hoffmann, Michele
Kroeger, Nicolaus
de Larrea, Carlos Fernandez
Pabst, Thomas
Gagelmann, Nico
HEMASPHERE, 2025, 9 (01):
[2] Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie's choice for patients with relapsed refractory multiple myeloma
Davis, James
McGann, Mary
Shockley, Abigail
Hashmi, Hamza
EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (06) : 473 - 475
[3] A Comparison of Standard of Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel CAR T-cell Therapy in Relapsed or Refractory Multiple Myeloma
Hansen, Doris
Peres, Lauren
Dima, Danai
Richards, Alicia
Shune, Leyla
Afrough, Aimaz
Midha, Shonali
Dhakal, Binod
Kocoglu, Mehmet H.
Ferreri, Christopher
Davis, James
Herr, Megan
Forsberg, Peter
Janakiram, Murali
Reshef, Ran
Sborov, Douglas W.
Khouri, Jack
Richard, Shambavi
Martin, Thomas
Lin, Yi
Patel, Krina
Sidana, Surbhi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S5 - S5
[4] The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US
Buthainah Ghanem
Lu Shi
BioDrugs, 2022, 36 : 773 - 780
[5] The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US
Ghanem, Buthainah
Shi, Lu
BIODRUGS, 2022, 36 (06) : 773 - 780
[6] Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Munshi, Nikhil C.
Anderson, Larry D., Jr.
Shah, Nina
Madduri, Deepu
Berdeja, Jesus
Lonial, Sagar
Raje, Noopur
Lin, Yi
Siegel, David
Oriol, Albert
Moreau, Philippe
Yakoub-Agha, Ibrahim
Delforge, Michel
Cavo, Michele
Einsele, Hermann
Goldschmidt, Hartmut
Weisel, Katja
Rambaldi, Alessandro
Reece, Donna
Petrocca, Fabio
Massaro, Monica
Connarn, Jamie N.
Kaiser, Shari
Patel, Payal
Huang, Liping
Campbell, Timothy B.
Hege, Kristen
San-Miguel, Jesus
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (08): : 705 - 716
[7] Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma (FEB, JCO-24-01730, 2025)
Hansen, Doris K.
Peres, Lauren C.
Dima, Danai
Richards, Alicia
Shune, Leyla
Afrough, Aimaz
Midha, Shonali
Dhakal, Binod
Kocoglu, Mehmet H.
Atrash, Shebli
Ferreri, Christopher
Castaneda, Omar
Davis, James A.
Bhurtel, Evguenia
McGuirk, Joseph
Wagner, Charlotte
Bansal, Radhika
Costello, Patrick
Smith, Kinaya
Lieberman-Cribbin, Alex
De Avila, Gabriel
Purvey, Sneha
Hosoya, Hitomi
Mikkilineni, Lekha
Oswald, Laura B.
Kaur, Gurbakhash
Pasvolsky, Oren
Gaballa, Mahmoud
Herr, Megan M.
Forsberg, Peter
Janakiram, Murali
Htut, Myo
Maringanti, Sireesha Asoori
Kalariya, Nilesh
Hashmi, Hamza
Reshef, Ran
Sborov, Douglas W.
Nadeem, Omar
Anwer, Faiz
Khouri, Jack
Raza, Shahzad
Atanackovic, Djordje
Alsina, Melissa
Freeman, Ciara L.
Locke, Frederick L.
Voorhees, Peter
Anderson Jr, Larry D.
Richard, Shambavi
Martin, Thomas
Lin, Yi
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (11) : 1399 - 1399
[8] A Real-World Comparison of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel CAR-T Therapy: A Single Center Experience for Relapsed/ Refractory Multiple Myeloma
Gill, Sarvarinder Kaur
Biran, Noa
Phull, Pooja
Vesole, David H.
Siegel, David S.
Parmar, Harsh
BLOOD, 2023, 142
[9] Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis
Amoozgar, Behzad
Bangolo, Ayrton, I
Uesole, David H.
Siegel, David S.
Biran, Noa
Phull, Pooja
Donato, Michele L.
Parmar, Harsh
BLOOD, 2024, 144 : 2408 - 2409
[10] In vivo expansion patterns of anti-BCMA CAR T-cell in relapsed/refractory multiple myeloma: Comparative immunomonitoring of idecabtagene vicleucel and ciltacabtagene autoleucel
Kocoglu, Mehmet
Rapoport, Aaron P.
Gebru, Etse
Omili, Destiny
Yamoah, Daniel
Mulatu, Rediet
Yared, Jean
Hardy, Nancy M.
Kallen, Michael
Badros, Ashraf Z.
Atanackovic, Djordje
CANCER RESEARCH, 2024, 84 (06)

← 1 2 3 4 5 →